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Abstract
Introduction: Enteropathic arthritis is one of the recognized extraintestinal manifestations of inflammatory bowel
disease and affects up to 25% of patients. The treatment options for refractory disease were rather limited and
ineffective until the arrival of biologic therapy in the last few years. The use of etanercept was unique for this
disease.
Case presentation: In this case report, a 58-year-old Malay woman with a 17-year history of ulcerative colitis had
persistent left knee effusion and synovitis for seven years, despite remission of the primary disease. She had had
multiple courses of systemic and intra-articular steroid that caused significant systemic side effects such as impaired
fasting glucose, hypertension, cataract, and weight gain. She also had a total left knee replacement for secondary
osteoarthritis. But the left knee synovitis and effusion recurred a month after the total knee replacement, and she
was subjected to a total synovectomy the following year. In view of failure of remission despite multiple
immunosuppressants (100 mg of azathioprine daily, 1 g of sulfasalazine twice a day, 10 mg of prednisolone daily,
and 10 mg of methotrexate weekly), 25 mg of subcutaneous etanercept twice weekly was started. After 5 weeks of
treatment, complete resolution of left knee effusion and normalization of the inflammatory markers were shown.
This continued up to 12 months of follow-up while our patient was on etanercept and 10 mg of methotrexate
weekly. No relapse or serious side effects were noted.
Conclusions: This case demonstrates the efficacy of etanercept in recalcitrant enteropathic arthritis with no relapse
of the underlying colitis while on treatment. The usage of this tumor necrosis factor inhibitor was unique in this
case of rheumatology and gastroenterology.
Introduction
Enteropathic arthritis is the most common extraintest-
inal manifestation of inflammatory bowel disease (IBD)
and can affect up to 30% of patients [1]. It is a subset of
spondyloarthritides and seronegative arthritis, which is a
group of inflammatory joint disease that usually affects
the enthesis or site of attachment of ligaments and ten-
dons to the bones [2]. There were three principal forms
of arthritis associated with IBD: the peripheral, the axial,
and a form overlapping between the two [3]. For periph-
eral arthritis, two types have been described in the lit-
erature: oligoarticular (type I) and polyarticular (type II)
[4]. Type I usually involves large joints of lower limbs
and is associated with IBD flares, whereas type II arthri-
tis is polyarticular and symmetric, usually evolves in
chronic disease, and involves not only hands and feet
but also large joints [4]. Type II may precede IBD symp-
toms, and its course is independent of IBD flares.
Corticosteroids are effective in acute cases; however,
in some refractory cases, the successful use of disease-
modifying anti-rheumatoid drugs (DMARDs) is rather
limited. Although there are no randomized controlled
trials on the efficacy of sulfasalazine, it is the most
widely used in enteropathic spondyloarthritis [5]. Meth-
otrexate and azathioprine are not as well studied and
often are ineffective [6]. Also, there were no reports of
regression of the enthesitis pathology in spondyloarthro-
pathies with the above DMARD therapies [7]. Analge-
sics, particularly non-steroidal anti-inflammatory drugs
(NSAIDs) and cyclo-oxygenase-2 inhibitors, should be
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used cautiously as they can exacerbate bowel symptoms
[5]. The recent introduction of anti-tumor necrosis fac-
tor-alpha (anti-TNF-a) has emerged as a promising
therapeutic opportunity and should be considered early
in patients whose condition is not sufficiently controlled
with DMARDs or in those with axial diseases.
In this case report, a very recalcitrant IBD-related
arthropathy or enteropathic arthritis is described in a
patient with ulcerative colitis that finally responded to
etanercept. The use of this type of TNF-a was unique
for this disease. The literature reviews in regard to the
use of biologics in enteropathic arthritis will be dis-
cussed further in this case report.
Case presentation
A 58-year-old Malay woman had ulcerative colitis that
was diagnosed 21 years ago when she presented with
recurrent diarrhea. Five years ago, she started to develop
peripheral polyarthritis. There were no other extra-
articular manifestations such as uveitis or pyoderma
gangrenosum. She had multiple relapses of colitis with
polyarthritis and therefore had received multiple courses
of tapering-dose oral prednisolone with maintenance of
1 g of mesalazine three times a day and subsequently
100 mg of azathioprine once daily. Finally, two years
later, with the above treatment, the primary disease
managed to be brought to remission.
In spite of the clinical and histological remission of
the IBD, the left knee arthritis seems to be persistent,
but other peripheral joints mentioned above were in
remission without any permanent deformity. A clinical
assessment revealed that the left knee was swollen,
warm, and tender. The inflammatory marker C-reactive
protein was increased to 1.14 mg/dL (normal is less
than 0.5 mg/dL). A knee aspirate revealed clear synovial
fluid and did not yield any growth. She received two
courses of 500 mg of intravenous methylprednisolone
daily for three days followed by a tapering dose of oral
prednisolone for one year for active and persistent left
knee arthritis, but the effects were temporary. Mesala-
zine was changed to 1 g of sulfasalazine twice a day, and
the azathioprine dose was subsequently increased to 150
mg once daily. Unfortunately, she developed leukopenia;
therefore, the azathioprine dose had to be reduced back
to 100 mg daily. Despite aggressive treatment with mul-
tiple courses of high-dose systemic and local steroid
with the maximum tolerated doses of sulfasalazine and
azathioprine, she still had recurrent left knee effusion
and synovitis. Indeed, the disease had caused significant
pain and restriction of mobility. Also, after almost two
years of corticosteroid therapy, our patient has endured
significant iatrogenic morbidity, including Cushingoid
habitus, impaired fasting glucose, hypertension, and
bilateral cataract with increased intraocular pressure.
In view of persistent unbearable pain and swelling of
the left knee with severe secondary osteoarthritis, a total
left knee replacement was done in the same year. Dur-
ing the operation, there was active synovitis of the left
knee, and a histopathological examination of the syno-
vial tissue revealed ‘rice bodies’, which are fibrocollagen-
ous connective tissue stroma admixed with fibrinous
exudates and abundant foci of vascular proliferation,
suggestive of inflammatory arthritis (Figure 1). One
month after the operation, the left knee effusion
recurred and there was persistent elevation of the
inflammatory markers. Subsequently, a left knee arthro-
scopic debridement and near-total synovectomy were
performed five years ago. Ten milligrams of oral metho-
trexate weekly was added one month after the operation,
on top of 1 g of sulfasalazine twice a day, 10 mg of pre-
dnisolone once daily, and 100 mg of azathioprine once
daily. Unfortunately, despite the above treatment for
four months, our patient continued to show poor
response and persistent recurrence of knee effusion.
Subsequently, 25 mg of subcutaneous etanercept twice
weekly, together with the other DMARDs and
azathioprine, was initiated after three months.
Eventually, the joint showed resolution of knee joint
swelling and synovitis at the fifth week of treatment,
visual analogue scale score improved from 70 to 20 mm,
and the C-reactive protein level decreased to 0.8 mg/dL.
After six months of treatment with etanercept,
azathioprine was stopped and sulfasalazine was changed
to 1 g of mesalazine three times a day as our patient
had a mild flare of ulcerative colitis with community-
acquired pneumonia. The steroid was also tapered off
after six months of treatment.
Twenty-five milligrams of subcutaneous etanercept
biweekly and 10 mg of methotrexate weekly were con-
tinued, and after 12 months of follow-up, the colitis or
arthritis was in remission and no serious side effects
were noted.
Discussion
The above case demonstrates the challenges in mana-
ging enteropathic arthritis given that the therapeutic
options for patients with the more severe form have
been rather limited. Commonly, oligoarthritis associated
with IBD is associated with disease activity; however, in
10% of cases, it evolves into chronic arthritis [4] as in
this case. Even though sulfasalazine seems to be promis-
ing in IBD-related arthropathy [8], our patient did not
show a good response with the treatment, indicating the
need for biologic therapy.
Although biologic treatment is a promising treatment
option, the trials of this agent involved mainly other
spondyloarthropathies, particularly ankylosing spondyli-
tis (AS) and psoriatic arthritis [9-11]. No randomized
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controlled trials have investigated therapeutic options in
IBD-related arthropathy. The treatment is based almost
entirely on extrapolation from treatment of other forms
of spondyloarthropathies since they shared the same
pathogenesis, which involves significant expression of
TNF-a in the joint spaces as the major inflammatory
mediators.
Among the biologic agents, infliximab, which is a chi-
meric anti-TNF-a monoclonal IgGI antibody, is the
most widely used and has been proven in many studies
to control the primary IBD and associated arthritis
[12,13]. For etanercept, only one small study by Marzo-
Ortega and colleagues [14] showed its efficacy in various
spondyloarthritides, including IBD. In that study, the
authors reported a significant increase in mean bone
mineral density at the hip and spine in all patients who
were treated with a six-month course of 25 mg of sub-
cutaneous etanercept biweekly [14]. Etanercept may
improve joint symptoms, but studies do not show any
benefit for the bowel inflammation as the treatment
progresses [15]. It has been proposed that the differen-
tial effects of infliximab and etanercept in IBD are due
to the inability of the etanercept to bind directly to the
cell surface of macrophages causing different signal was
transmitted into the cell via transmembrane TNF. These
signals do not induce mononuclear cells apoptosis
within the bowel mucosa, which is the key pathogenesis
in IBD [15]. Although adalimumab has also been shown
to be effective for the treatment of AS [16], no trials
have specifically examined the efficacy of adalimumab
for patients with concomitant IBD and arthritis. Table 1
[17-21] summarizes the previous studies of anti-TNF in
enteropathic arthritis.
Although etanercept is not effective for bowel symp-
toms in IBD, it was started in this patient because she
preferred to administer the subcutaneous medications
herself at home and because her underlying colitis was
in remission. Although there has been a concern of a
potential flare of underlying IBD with etanercept, [22]
our patient had no relapse of colitis after 12 months of
Figure 1 Synovial tissue of the left knee (hematoxylin and eosin staining, ×400). A fragment of fibrocollagenous connective tissue stroma
admixed with fibrinous exudates and abundant foci of vascular proliferation indicates an inflammatory process.
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treatment and the underlying arthritis remained in
remission.
Despite all of the potential benefits of the biologics,
we still have an unresolved issue pertaining to the dura-
tion of the treatment. In other spondyloarthritis such as
AS and psoariatic arthritis, a sustained response of up
to two years was reported [14,23]. Unfortunately, most
of these patients relapse after a few weeks of withdrawal
of the treatment. The relapse rate is high, ranging from
75% to 100%, and the mean time to relapse was
reported to be as early as six to 17.5 weeks. However,
retreatment is safe and still effective, resulting in similar
clinical improvement [24]. Therefore, the optimum
duration of the treatment is not known, and most likely
our patient will require lifelong and extremely expensive
treatment.
In Malaysia, the cost and feasibility of biologics are
indeed the major concern, and the treatment is available
only in large tertiary centers. To date, only a few studies
have looked into the cost-effectiveness of etanercept
among patients with other groups of seronegative
arthritis such as AS and psoariatic arthritis. The primary
outcome measure used was quality-adjusted life years
(QALYs), which was derived from utility values esti-
mated as function disability measured by the British
ankylosing spondylitis disease activity index (BASDAI),
British ankylosing spondylitis functional index (BASFI),
and EQ-5D scores. The results were rather conflicting
and inconclusive as different populations were involved
with different criteria of each patient, the time the TNF
blocker was started was not the same, and no rando-
mized control trials directly compared various anti-
TNF-a inhibitors. A study by Ara and colleagues [25]
demonstrated the potential cost-effectiveness of etaner-
cept plus NSAIDs compared with NSAIDs alone in
patients who had severe unremitting AS and who failed
two optimum NSAIDs in the UK, and the majority of
costs were below £25,000 per QALY at five years. Eta-
nercept is the only biologic within the range of cost-
effectiveness estimates considered by the National Insti-
tute for Health and Clinical Excellence to represent a
good value for money in the National Health Service
Table 1 Case series and studies of biologics in enteropathic arthritis

















Infliximab 5 mg/kg at 0 (luminal CD)
or 0, two, and six weeks (fistulizing
CD)
61% (35/59) improvement of 1 point in the
arthritis component of the
Crohn disease activity index (CDAI) score at
12 weeks and complete







11 inflammatory arthralgias (three active
synovitis)
11 axial/sacroilitis
Infliximab 5 mg/kg After two weeks,
partial improvement in duration of
morning stiffness, tender joint count, and
visual analogue scale for pain in 7/11
patients.
Clear improvement in frank arthritis in one







40 (SpA with or without inflammatory bowel
disease) versus placebo
Infliximab 5 mg/kg at 0, two, and six
weeks or placebo
At 12 weeks, improvement in patient and
physician global assessment (18 in
infliximab group versus 69 in placebo
group, P < 0.001) and physician global






24 CD with SpA (16 active CD and eight
inactive CD) versus 12 control subjects (active
CD treated with corticosteroids, azathioprine,
salicylates, and antibiotics)
Infliximab 5 mg/kg at 0, two, and six
weeks followed by 3 mg/kg (inactive
CD) or 5 mg/kg (active CD) every five
to eight weeks
Improvement of enthesitis or BASDAI or




10 (7 ankylosing spondylitis, two CD, and one
undifferentiated SpA)
Subcutaneous etanercept 25 mg
biweekly for 24 weeks
All patients achieving greater than 50%
improvement of
BASDAI at four weeks and throughout
study period
BASDAI, British ankylosing spondylitis disease activity index; CD: Crohn disease; SpA: sponyloarthropathy.
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[25]. On the other hand, the incremental cost-utility
ratios in The Netherlands vary between £43,000 and
£124,000 per QALY for etanercept compared with usual
care and £67,000 to £237,000 for infliximab [26]. Thus,
this model suggests that the high drug costs restrict effi-
cient use in all patients who have a BASDAI of more
than 4. Bravo and colleagues [27] demonstrated, among
patients with psoariatic arthritis, that, at a 10-year time
horizon, etanercept was more cost-effective than inflixi-
mab. The incremental cost-effectiveness ratio was signif-
icantly higher at £26,000 per QALY to £31,000 per
QALY for etanercept compared to £165,000 to 205,000
per QALY in infliximab with no superiority effective-
ness. However, this study was not a head-to-head
comparison.
Even though biologic treatment has demonstrated
marked clinical and radiological improvement in both
synovitis and enthesitis, thus preventing ankylosis in the
short term, it remains to be shown whether patients
benefit from long-term anti-TNF therapy and whether
radiologic progression and ankylosis can be stopped
totally. A study by Baraliakos and colleagues [28]
showed that, after two years of treatment, magnetic
resonance imaging revealed that minor spinal inflamma-
tion was still present in 64% of the patients. Therefore,
long-term treatment may not guarantee the prevention
of ankylosis, but at least it can delay the process and,
hopefully with longitudinal studies of early disease, will
be able to answer the question of whether these thera-
pies constitute true long-term disease modifiers in
spondyloarthropathies.
Conclusions
Etanercept seems to be promising in controlling the dis-
ease, but the long-term cost-effectiveness and its side
effects are yet to be proven. Further studies of these bio-
logic therapies need to be continued and hopefully will
offer better options to patients.
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